Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the browsers below.

Internet Explorer 10, Firefox, Chrome, or Safari.

Volunteer Advocate

News

Cystic Fibrosis Canada welcomes Kelly Grover as new Chief Executive Officer
April 24, 2018

TORONTO (April 24, 2018) — Cystic Fibrosis Canada’s (CF Canada) Board of Directors is pleased  to announce the appointment of Kelly Grover to the position of President and Chief Executive Officer (CEO) effective June 4, 2018.

“We are delighted to welcome Kelly Grover to the Cystic Fibrosis Canada family,” said Mitch LePage, Chair of the Board of Directors. “With over 20 years of experience in a variety of health-based organizations, we are confident in Kelly’s leadership and vision for the organization. Kelly’s appointment is the result of an extensive search process, and we are excited for her to bring a fresh perspective, pragmatic sensibility, and strategic vision to advance our cause.”

“Cystic Fibrosis Canada continues to be one of the leading CF organizations internationally. With the disease on the cusp of fundamental change, the opportunity to lead this organization is an extraordinary honour,” said Grover. “I look forward to working with our stakeholders and community to ensure change comes now for those living with cystic fibrosis.”

Grover’s focus will be on the continued implementation of our strategic plan, ONE CFocus 2020, ensuring that the national operational plans and strategic directions are aligned with this plan in the delivery of programs, revenue generation, communications and advocacy, clinical/scientific initiatives, and research.

Kelly Grover joins Cystic Fibrosis Canada from Ovarian Cancer Canada, where she served as the Vice President, National Programs and Partners. Grover’s previous roles have included leadership positions with Planned Parenthood, the Canadian Institutes of Health Research, Cancer Care Ontario and Breakfast for Learning. Her work has been focused primarily in the areas of program delivery, advocacy, communications and fund development in the health and charitable sectors.

-30-

About cystic fibrosis

Cystic fibrosis is the most common fatal genetic disease affecting Canadian children and young adults. It is a multi-system disease that affects mainly the lungs and the digestive system. In the lungs, where the effects are most devastating, a build-up of thick mucus causes severe respiratory problems. Mucus also builds up in the digestive tract, making it difficult to digest and absorb nutrients from food. As improved therapies have helped to address the malnutrition issues, most deaths related to cystic fibrosis are now due to lung disease. There is no cure. In Canada on average, one baby in 3,500 suffers from cystic fibrosis while in Québec, the average is one baby in 2,500.

Cystic Fibrosis Canada

Cystic Fibrosis Canada is one of the three principal charitable organizations committed to finding a cure for cystic fibrosis and is an internationally recognized leader in funding research, innovation and clinical care. Cystic Fibrosis Canada has invested more funding in life-saving CF research and care than any other non-governmental agency in Canada.  Since 1960, Cystic Fibrosis Canada has invested more than $244 million in leading research, care and advocacy, resulting in one of the world’s highest survival rates for Canadians living with cystic fibrosis.

 

For more information and media requests, please contact:

Jennifer Nebesky, Chief Marketing and Communications Officer

(416) 485-9149 ext. 248

jnebesky@cysticfibrosis.ca


Back to Listing